Real life study of the use of omalizumab for pediatric patients with multiple food allergies

Main Article Content

Judit Barrena Crespo
Marta Viñas Domingo
Nora Hernández Arauzo
M. José Castillo
M. Belén Delavalle
M. Pilar Saura Foix
Davinia Vázquez Sánchez
Adriana Izquierdo-Dominguez


Multiple food allergy, Oral Immunotherapy, omalizumab, anaphylaxis, total IgE, Food Allergy Quality of Life Questionnaire – Parent Form


Background: Multiple food allergies (MFAs) affect 30% of the child population with food allergy. The current treatment is the exclusion diet, which frequently affects the quality of life for these patients. The objective of the study was to describe the effect of omalizumab treatment in children diagnosed with MFAs who experienced frequent anaphylactic reactions and the impact on their quality of life.
Material and methods: A descriptive observational study. Patients with severe food restrictions and high-risk due to multiple episodes of anaphylaxis were included. The allergy was confirmed by compatible clinical, skin tests, positive specific IgE and oral food challenges (OFCs). Omalizumab treatment was initiated and the impact on the life quality of patients and their families was assessed using the validated Food Allergy Quality of Life Questionnaire-Parent Form.
Results: Five patients with an average age at diagnosis of 3.58 years (range between 1.5–7.9 years), were diagnosed with MFAs. All patients presented with anaphylaxis. All patients were treated with omalizumab between 2013 and 2019. Omalizumab treatment was initiated at a mean age of 6.05 years (range between 4.5–8.25 years). All patients have undergone OFC to reintroduce food successfully. 2 patients had their dose of omalizumab reduced by half, and 1 patient has had the time interval extended between administrations due to the maintenance of food tolerance. No immediate local or systemic adverse reactions were documented. Two patients have commenced omalizumab administration at home without incident.
Conclusions: Children with MFAs who are treated with omalizumab do not show reactions in response to most of the foods to which they previously had anaphylaxis. Consequently, these patients were able to significantly expand the variety of their diet, improving the life quality and avoid anaphylaxis following the inadvertent intake of these foods.

Abstract 392 | PDF Downloads 288 XML Downloads 0 HTML Downloads 5


1. Gupta RS, Springton EE, Warrier MR, Smith B, Kumar R, Pongracic J, et al. The prevalence, severity, and distribution of childhood food allergy in the United States. Pediatrics. 2011;128:9−17.

2. McGowan EC, Keet CA. Prevalence of self-reported food allergy in the National Health and Nutrition Examination Survey (NHANES) 2007–2010. J Allergy Clin Inmunol. 2013;132: 1216−19.

3. Branum AM, Lukacs SL. Food Allergy among children in the United States. Pediatrics. 2009;124:1549−55. 10.1542/peds.2009-1210

4. Gupta RS, Dyer AA, Jain N, Greenhawt MJ. Childhood food allergies: current diagnosis, treatment, and management strate-gies. Mayo Clin Proc. 2013;88:512−26. j.mayocp.2013.03.005

5. Ojeda P, Sastre J, Olaguibel JM, Chivato T. Alergológica 2015: a national survey on allergic diseases in the adult Spanish population. J Investig Allergol Clin Immunol. 2018;28:151−64.

6. Sicherer SH, Sampson HA. Food allergy. J Allergy Clin Immunol. 2010;125:116−25.

7. Shah E, Pongracic J. Food-induced anaphylaxis: who, what, why and where? Pediatr Ann. 2008;37:536−41. 10.3928/00904481-20080801-06

8. Martorell A, Alonso E, Boné J, Echeverría L, López MC, Martín F, et al. Food allergy committee of SEICAP. Position document: IgE-mediated allergy to egg protein. Allergol Immunopathol. 2013;41:320−36.

9. Nagakura K, Sato S, Yanagida N, Ebisawa M. Novel immuno-therapy and treatment modality for severe food allergies. Curr Opin Allergy Cin Immunol. 2017;17:212−19. https://doi. org/10.1097/ACI.0000000000000365

10. Sampson HA, van Wijk RG, Bindslev-Jensen C, Sicherer SH, Teuber S, Burks W, et al. Standardizing double-blind, placebo-controlled oral food challenges: American Academy of Allergy, Asthma & Immunology-European Academy of Allergy and Clinical Immunology PRACTALL consensus report. J Allergy Clin Immunol. 2012;130(6):1260−74. https://doi. org/10.1016/j.jaci.2012.10.017

11. Sampson HA, Leung DY, Burks AW, Lack G, Bahna SL, Jones SM, et al. A phase II, randomized, double-blind, parallel-group, placebo-controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy. J Allergy Clin Immunol. 2011;127:1309−10.

12. Wood RA, Kim JS, Lindblad R, Nadeau K, Henning AK, Dawson P, et al. A randomized, double-blind, placebo-controlled study of omalizumab combined with oral immunotherapy for the treatment of cow’s milk allergy. J Allergy Clin Immunol. 2016;137:1103−10.

13. Bégin P, Dominguez T, Wilson SP, Bacal L, Mehrotra A, Kausch B, et al. Phase 1 results of safety and tolerability in a rush oral immunotherapy protocol to multiple foods using Omalizumab. Allergy, Asthma Clin Immunol. 2014;10:7. https://

14. Labrosse R, Graham F, Des Roches A, Bégin P. The use of Omalizumab in food oral immunotherapy. Arch Immunol Therap Exp. 2017;65:189−99.

15. Fiocchi A, Artesani MC, Riccardi C, Mennini M, Pecora V, Fierro V, et al. Impact of omalizumab on food allergy in patients treated for asthma: a real-life study. J Allergy Clin Immunol Pract. 2019;7:1901−09. jaip.2019.01.023

16. Mendonca V, Pauperio S, Trindade E, Amil J, Bonito Vitor, A. Omalizumab in pediatric patients with severe food allergy. Allergy. 2011;66:1−104. Abstract 135. j.1398-9995.2011.02604.x

17. Slavin RG, Ferioli C, Tannenbaum SJ, Martin C, Blogg M, Lowe PJ. Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. J Allergy Clin Immunol. 2009;123:107−13.